Open an account

Cellebrite DI

CLBT · NASDAQ

$11.37+$0.225 (+2.02%)TodayMarket closed ·
Prev close $11.15

About CLBT

Cellebrite DI Ltd. engages in the provision of digital investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The company is headquartered in Petah Tikva, Central(Hamerkaz) and currently employs 1,285 full-time employees. The company went IPO on 2021-08-31. The firm is committed to providing a Digital Intelligence (DI) platform for managing DI in legally sanctioned investigations. The firm provides solutions for the public and private sectors, enabling organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. The firm's platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. The firm aims to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world.

Employees
1,285
Headquarters
Petah Tikva, Central(HaMerkaz)
Listed
Aug 31, 2021
Sector
Information Technology
Industry
Software
Website
cellebrite.com

CLBT key statistics

Market cap
2.86B
Price-earnings ratio
50.66
Dividend yield
—
Average volume
2.32M
Volume
1.27M
Open price
$11.24
High today
$11.43
Low today
$11.13
52 Week high
$19.98
52 Week low
$9.58

Cellebrite DI (CLBT) at a glance

Cellebrite DI (CLBT) last traded at $11.37, with a market cap of 2.86B and a price-to-earnings ratio of 50.66.

Today the stock has traded between $11.13 and $11.43. The current price is 2.2% above the day's low and 0.5% below its high.

Volume so far is 1.27M shares, below the average of 2.32M shares a day.

Over the past year Cellebrite DI has ranged from $9.58 to $19.98, and now sits 17% of the way up that range.

Cellebrite DI met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.11 per share against an estimate of $0.1129.

The average analyst price target is $16.31, 43.4% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $16.31
Low
$12.63
Now
$11.37
High
$21.43

CLBT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 16.7% on average.

  1. Q3 FY24: reported $0.14 per share against an estimate of $0.0889
  2. Q4 FY24: reported $0.10 per share against an estimate of $0.0991
  3. Q1 FY25: reported $0.10 per share against an estimate of $0.0863
  4. Q2 FY25: reported $0.12 per share against an estimate of $0.1064
  5. Q3 FY25: reported $0.14 per share against an estimate of $0.1278
  6. Q4 FY25: reported $0.14 per share against an estimate of $0.1382
  7. Q1 FY26: reported $0.12 per share against an estimate of $0.101
  8. Q2 FY26: reported $0.11 per share against an estimate of $0.1129

CLBT news

  • Press releasePRNewswire

    Cellebrite to Report Third-Quarter 2026 Financial Results on November 12, 2026

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellebrite DI Ltd. - CLBT

  • Press releaseNewsfile

    Kaplan Fox Shareholder Alert: Cellebrite DI Ltd. (CLBT) is Under Investigation for Possible Securities Law Violations

  • Press releaseNewsfile

    Kaplan Fox is Investigating Cellebrite DI Ltd. (CLBT) for Investors Who Suffered Losses

  • Press releaseNewsfile

    Kaplan Fox Urges Investors of Cellebrite DI Ltd. (CLBT) with Losses to Contact the Firm

  • Press releaseNewsfile

    Kaplan Fox Reminds Investors of Cellebrite DI Ltd. (CLBT) of an Ongoing Securities Investigation

  • Press releaseNewsfile

    Kaplan Fox Is Investigating Cellebrite DI Ltd. (CLBT) on Behalf of Shareholders for Possible Securities Law Violations

  • Press releaseNewsfile

    Kaplan Fox Advises Investors of Cellebrite DI Ltd. (CLBT) to Contact the Firm Regarding a Securities Investigation

Similar companies

Companies in the same industry as Cellebrite DI

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.